{"entity":{"id":"universal-dx","kind":"company","name":"Universal DX","aka":[],"tldr":"Universal DX is developing Signal-C, a blood test to screen for bowel cancer and pre-cancerous growths, and has partnered with Quest Diagnostics to offer it in the US once regulators approve it.","summary":"Universal DX (UDX), incorporated in Spain in 2012 and headquartered in Madrid, develops cell-free DNA blood tests for early cancer detection. Its lead assay, Signal-C, uses next-generation sequencing of methylation and fragmentation patterns in circulating DNA with machine learning to detect colorectal cancer and advanced adenomas. In a 1,000-patient study at Digestive Disease Week 2023 it showed 93 percent sensitivity for colorectal cancer and 54 percent for advanced adenomas at 92 percent specificity. A 15,000-patient, 100-site FDA registrational trial (NCT06059963) enrolled its first patient in January 2024, with Quest's Lewisville, Texas laboratory as the single testing site. UDX announced a Series B initial close of about $70 million in November 2023 including Quest, completed in August 2024 with new investor Olympus Innovation Ventures.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.universaldx.com/"},{"label":"Quest collaboration and Series B initial close (Nov 2023)","url":"https://cdn.prod.website-files.com/60925e59116a323839bdf90a/655b7ee215dc0e6a169bd932_2023_11_19%20UDX%20US%20Press%20release.pdf"},{"label":"Series B close and FDA trial (Aug 2024)","url":"https://cdn.prod.website-files.com/60927bf52450bc2ed1129413/66bceb91587a66e050bd59a6_2024_08%20UDX%20PR%20release%20Series%20B%20Extension.pdf"},{"label":"Press page","url":"https://www.universaldx.com/press"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["early-detection","diagnostics"],"technologies":["liquid-biopsy","methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["US office moved from Cambridge, MA (2023-2024 releases) to Dallas, TX (current website). Series B extension amount not disclosed."],"hq":"Madrid","country":"ES","companyType":"diagnostics","website":"https://www.universaldx.com/","founded":2012,"stage":"startup","investors":[],"funding":[{"round":"Series B","year":2023,"amountUsd":70000000,"source":"https://cdn.prod.website-files.com/60925e59116a323839bdf90a/655b7ee215dc0e6a169bd932_2023_11_19%20UDX%20US%20Press%20release.pdf","note":"Initial closing of approximately $70 million with investors including Quest Diagnostics, announced 20 November 2023."},{"round":"Series B","year":2024,"source":"https://cdn.prod.website-files.com/60927bf52450bc2ed1129413/66bceb91587a66e050bd59a6_2024_08%20UDX%20PR%20release%20Series%20B%20Extension.pdf","note":"Series B closed August 2024 with existing investors including Quest Diagnostics and new investors including Olympus Innovation Ventures; extension amount not disclosed."}]},"route":"/companies/universal-dx/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}]}}